Form 4: Regeneron Director Arthur F. Ryan Sells Shares Under 10b5-1 Plan

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Arthur F. Ryan, a director of Regeneron Pharmaceuticals, Inc., reported the sale of company stock on June 3, 2024.
• The sales were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on August 7, 2023.
• A total of 99 shares of common stock were sold at varying prices, ranging from $979.40 to $1,000.04 per share.
• The sales resulted in a decrease in Ryan's direct holdings, with the remaining balance being 17,982 shares.
• The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the Commission staff, the Company, or a security holder of the Company.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports a stock sale under a pre-existing 10b5-1 plan, which is a common and legal practice.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. It is important to consider the overall context of insider transactions, including the reasons for the sales and the overall financial health of the company.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant impact given that it was pre-planned.

Key Dates